Comparing daily aspirin doses in high-risk MPN patients with aspirin resistance
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk Myeloproliferative Neoplasms Patients With Aspirin Resistance
This study is testing whether taking aspirin once a day or twice a day can help high-risk patients with blood disorders reduce the risk of blood clots.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Siriraj Hospital Academic / other |
| Locations | 1 site (Bangkok Noi, Bangkok) |
| Trial ID | NCT06740916 on ClinicalTrials.gov |
What this trial studies
This study investigates the long-term efficacy of administering aspirin once daily versus twice daily in patients with myeloproliferative neoplasms (MPN) who exhibit laboratory aspirin resistance. It involves a prospective randomized design where eligible adult patients will be assigned to one of the two aspirin dosing regimens. Platelet function testing will be conducted at baseline, one month, and six months to assess aspirin resistance, while clinical outcomes related to thrombosis and side effects will be monitored for at least two years. The aim is to determine if increasing the aspirin dose can effectively reduce thrombotic events in this high-risk population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with Philadelphia-negative myeloproliferative neoplasms who show laboratory aspirin resistance.
Not a fit: Patients with active cancer, thrombocytopenia, or those not exhibiting aspirin resistance will likely not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective aspirin dosing strategy to prevent thrombotic events in high-risk MPN patients.
How similar studies have performed: While there is limited data on this specific approach, studies on aspirin dosing in other populations have shown varying degrees of success, making this a potentially novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Philadelphia negative Myeloproliferative neoplasms aged at least 18 years old Exclusion Criteria: * Concomitant other active malignancy or cured less than 6 months * Platelet count less than 50,000/microL * Receiving anticoagulant * Active peptic ulcer * Active bleeding or Planning to undergo procedure/operation with bleeding risk * No laboratory aspirin resistance with LTA method
Where this trial is running
Bangkok Noi, Bangkok
- Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital — Bangkok Noi, Bangkok, Thailand (Recruiting)
Study contacts
- Study coordinator: Yingyong Chinthammitr, MD, RCPT, Thai board of hemato
- Email: dryingyong@gmail.com
- Phone: +66 + 0814264252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.